BMO Raises Incyte Price Target to $112 on Opzelura Strength

BMO Capital Markets has raised its stock price target for Incyte Corporation to $112, citing the strong performance of the company's dermatology drug Opzelura. Analysts noted that Opzelura sales have exceeded expectations, positively impacting Incyte's revenue outlook. BMO expects the drug to continue gaining market share and supporting the company's growth potential. The new target implies significant upside from current levels. BMO expressed confidence in Incyte's drug portfolio and the long-term success of Opzelura. This is not investment advice.

📊 INCY — Piyasa Yorumu

■ neutral · 60%

Although the news highlights the positive effect of Opzelura, the target price of $112 remains below the current price of $116.70. Technical indicators present mixed signals: RSI is neutral at 48.9, MACD is below the signal line but near zero, and the price is slightly below the 20-day moving average of $117.18. Determining a clear short-term direction is difficult, thus a neutral stance is recommended.

RSI 14

48.9

MACD

0.03

24h Δ

-0.87%

📊 BMO — Piyasa Yorumu

▲ up · 60%

BMO shares closed at $179, trading above both the 20-day and 50-day moving averages, indicating a short-term uptrend. The RSI stands at 65, not yet in overbought territory, while the MACD shows positive momentum above the signal line. A news headline highlights BMO raising its price target for Incyte, citing the impact of Opzelura, reflecting a positive outlook on the pharmaceutical sector and underscoring BMO's analytical expertise. However, since this news pertains to BMO's assessment of another company rather than its own stock performance, its direct impact may be limited. Combined with the positive technical signals and the general optimism generated by the news, the stock is likely to move upward in the short term.

RSI 14

65.2

MACD

0.81

24h Δ

0.33%

Canlı Grafikler